M&A Deal Summary

Horizon Therapeutics Acquires Viela Bio

On February 1, 2021, Horizon Therapeutics acquired life science company Viela Bio from HBM Partners AG for 3.1B USD

Acquisition Highlights
  • This is Horizon Therapeutics’ 10th transaction in the Life Science sector.
  • This is Horizon Therapeutics’ largest (disclosed) transaction.
  • This is Horizon Therapeutics’ 9th transaction in the United States.
  • This is Horizon Therapeutics’ 1st transaction in Maryland.

M&A Deal Summary

Date 2021-02-01
Target Viela Bio
Sector Life Science
Buyer(s) Horizon Therapeutics
Sellers(s) HBM Partners AG
Deal Type Add-on Acquisition
Deal Value 3.1B USD
Advisor(s) Goldman Sachs (Financial)
Mintz Levin Cohn Ferris Glovsky and Popeo PC (Legal)

Target

Viela Bio

Gaithersburg, Maryland, United States
website
Viela Bio is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Viela Bio was founded in 2018 and is based in Gaithersburg, United States.

Search 191,543 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Horizon Therapeutics

Dublin, Ireland

website


Category Company
Founded 2005
Sector Life Science
Employees2,100
Revenue 3.2B USD (2021)
DESCRIPTION

Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Therapeutics was founded in 2005 and is based in Dublin, Ireland.


DEAL STATS #
Overall 10 of 11
Sector (Life Science) 10 of 11
Type (Add-on Acquisition) 7 of 7
State (Maryland) 1 of 1
Country (United States) 9 of 9
Year (2021) 1 of 2
Size (of disclosed) 1 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-04-02 Curzion Pharmaceuticals

San Diego, California, United States

Curzion Pharmaceuticals, Inc. is a development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825). Curzion Pharmaceuticals was founded in 2019 and is based in San Diego, California.

Buy $45M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-17 OPKO Health - Sterile Fill & Finish Manufacturing Facility

Waterford, Ireland

OPKO Health - Sterile Fill & Finish Manufacturing Facility engages in the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale.

Buy $65M

Seller(S) 1

SELLER

HBM Partners AG

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 2001
PE ASSETS 3.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.


DEAL STATS #
Overall 7 of 11
Sector (Life Science) 7 of 11
Type (Add-on Acquisition) 1 of 1
State (Maryland) 1 of 1
Country (United States) 5 of 8
Year (2021) 1 of 4
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-15 Farmalisto

Bogotá, Colorado, United States

Farmalisto is a technology healthcare platform in Latin America that connects providers and users of the healthcare system to enhance value creation and delivery to end customers. Currently active in Colombia and Mexico as a online pharmacy. Farmalisto is expanding its services to become a partner of choice for pharmaceutical companies in logistics, marketing and disease management. Farmalisto was founded in 2013 and is based in Bogotá ,Colorado. ,

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-11 Antiva Biosciences

Brisbane, California, United States

Antiva Biosciences is a developing novel topical therapies to treat pre-cancerous lesions caused by HPV, before they progress to cervical cancer. Antiva Biosciences was founded in 2012 and is based in Brisbane, california.

Buy -